Oncology Billing Guide 2026

Chemotherapy, Infusion Therapy, and Drug Administration Coding

Published June 10, 2026 · Updated October 15, 2026 · 14 min read · By Yagnesh Dave

Oncology billing is among the most complex, and highest-stakes, billing environments in medicine. A single chemotherapy infusion visit can generate thousands of dollars in billable services, mostly drug, and a single coding error on infusion sequencing, drug administration hierarchy, or concurrent therapy rules can cost that entire claim. Oncology denials are driven primarily by infusion hierarchy errors, prior authorization failures for high-cost drugs, and documentation shortfalls on medical oncology E/M visits.

This guide covers the five pillars of oncology revenue: chemotherapy administration coding, infusion therapy hierarchy rules, oncology E/M billing, drug administration (non-chemo), and prior authorization management for biologics and targeted therapies.

1. Chemotherapy Infusion CPT Codes (96413–96417)

Chemotherapy infusion CPT codes start with 96413 for the first hour, 96415 for each additional hour, and 96417 for each additional sequential drug. 96409 and 96411 cover IV push, 96416 starts infusions over 8 hours using a pump, and 96401 covers subcutaneous or intramuscular injections.

Chemotherapy administration codes differ from standard infusion codes and carry higher reimbursement rates. The correct code depends on the route of administration (IV push vs. infusion), the duration, and whether it is the primary service of the visit or an add-on concurrent with another service.

Infusion Hierarchy Rule: the Most Misunderstood Rule in Oncology Billing

When multiple infusion services are provided in a single visit, the infusion hierarchy determines which code is billed as the "primary" service and which are add-ons. This is not the order in which drugs were given; it is a hierarchy of service type:

1. Chemotherapy infusion (96413): always primary if performed, regardless of whether it started first
2. Chemotherapy IV push (96409): primary if no chemo infusion occurred
3. Therapeutic/diagnostic infusion (96365): primary only if no chemo administered
4. Hydration (96360): never the initial code when another infusion is present; a separate sequential hydration run of more than 30 minutes reports as the add-on 96361, and concurrent hydration isn't billable

Common error: billing hydration (96360) as the primary service when the patient also received chemotherapy. Correct: 96413 is primary. Hydration given at the same time isn't reportable, and a separate sequential hydration run of more than 30 minutes reports as the add-on 96361. Billing them in the wrong hierarchy order causes systematic denials.

Where the hierarchy applies matters. Payer policies built on the CPT guidelines apply it in facility settings such as a hospital outpatient department. In a physician office, the initial code is the one that best describes the primary reason for the encounter, whatever order the drugs were given. Check the payer's policy for your place of service.

FOLFOX CPT Codes: A Worked Example

FOLFOX is commonly reported with 96413 and 96415 for oxaliplatin, 96368 once for concurrent leucovorin, 96411 for the 5-FU push, and 96416 to start the 5-FU pump. Drug lines use J9263, J0640 and J9190. Confirm pump disconnect rules with each payer.

FOLFOX combines oxaliplatin, leucovorin and fluorouracil (5-FU). A commonly reported pattern looks like this:

• Oxaliplatin (J9263): 96413, plus 96415 for each additional hour
• Leucovorin (J0640) running at the same time: 96368, once, regardless of how long it runs
• 5-FU push (J9190): 96411, because another chemo infusion is the initial service
• 5-FU pump (J9190): 96416 to start the ambulatory pump

Pump disconnect and cassette refill rules vary. Check NCCI edits and each payer's policy, and don't report 96521 on the same date as 96416. Coders disagree on a few of these details, so have a certified coder confirm the pattern against your payers before you build a charge template.

2. Non-Chemo Infusion and Therapeutic Drug Administration

Most oncology visits include non-chemotherapy drugs such as antiemetics, growth factors and other supportive care. These are billed using the therapeutic infusion codes (96365–96368), not the chemotherapy codes, and follow the same hierarchy logic. Monoclonal antibodies and other biologics are covered in the immunotherapy section below.

Immunotherapy and Checkpoint Inhibitors

Checkpoint inhibitors (pembrolizumab/Keytruda, nivolumab/Opdivo, atezolizumab/Tecentriq) are monoclonal antibodies. The Medicare Claims Processing Manual (Chapter 12, section 30.5) extends the chemotherapy administration codes to monoclonal antibody agents and other biologic response modifiers, so these drugs are often reported with 96413 rather than 96365. Since January 2025 the manual also says contractors can weigh the intensity of the service and not just the drug name, so the MAC's or payer's policy decides which family applies:

• Check your MAC's billing article for each drug before you choose between the 96413 and 96365 families, and expect commercial payers to differ
• When immunotherapy is given on the same day as another chemo-category drug, 96413 is the initial code and the second drug is typically an additional sequential infusion (96417); if your payer treats the drug as non-chemo, 96367 or 96368 applies instead
• Prior authorization is required for virtually every checkpoint inhibitor and must specify the diagnosis, line of therapy, and biomarker status (PD-L1, TMB, MSI) for approval

3. Oncology E/M Visits: New Patient vs. Established

Medical oncology E/M visits are among the most undervalued in oncology practice. The complexity of cancer care (multiple co-morbidities, treatment toxicity management, prognostic discussions) routinely justifies 99214 and 99215 coding, yet most practices default to 99213 out of misplaced caution.

Scoring Oncology Visits Under 2021 AMA Guidelines

The 2021 E/M guidelines determine level by either Medical Decision Making (MDM) or Total Time. Oncology visits qualify for high-level coding on both pathways:

• 99215: High complexity MDM: Patient with cancer on active treatment, reviewing labs, managing toxicities, coordinating with radiation/surgery, discussing prognosis, this is high complexity MDM. Document: number of diagnoses/management options addressed, amount/complexity of data reviewed (lab results, imaging, pathology), risk of complications/morbidity/mortality
• 99215: Time: 40–54 minutes total time including pre/post-visit documentation. Most new oncology consultations and complex follow-ups exceed this threshold
• 99214: Moderate complexity MDM: Established patient, stable on maintenance therapy, labs reviewed, no toxicity, moderate complexity when 2+ chronic conditions addressed

Same-Day E/M with Infusion (Modifier 25)

An oncology E/M visit on the same day as chemotherapy infusion requires modifier 25 on the E/M code. Without modifier 25, most payers bundle the E/M into the infusion service and deny it. Key documentation requirements:

• The E/M must be a separate, separately documented service, not just a pre-infusion check with vital signs
• Document: history, clinical assessment, medication review, toxicity evaluation, treatment plan decision, this constitutes a billable E/M independent of the infusion
• Medicare and most commercial payers allow same-day E/M with infusion when modifier 25 is applied and documentation supports a separate service

4. Drug Billing: J-Codes and Buy-and-Bill

Chemotherapy and infusion drugs are billed using HCPCS Level II J-codes. The buy-and-bill model, where the practice purchases drugs wholesale and bills payers at the allowed amount, represents a significant component of oncology practice revenue. Accurate drug billing requires precise dosing documentation and correct NDC (National Drug Code) reporting.

NDC Reporting Requirements

Medicare and many commercial payers require NDC (National Drug Code) reporting on all drug claims. Missing or incorrect NDC is a top claim denial driver in oncology:

• Report NDC in the format: qualifier (N4) + 11-digit NDC + unit qualifier (UN = units, ML = milliliters, GR = grams) + quantity
• Use the NDC from the vial actually administered, not a generic NDC or a reference NDC
• When multiple vials of the same drug are used in one session, report the NDC of each lot if different, or one NDC with combined quantity
• Drug wastage: when a partial vial is used and the remainder is discarded, bill the total dose administered (not the full vial) unless your payer contract allows wastage billing, verify per contract

5. Prior Authorization for Oncology Drugs

Prior authorization is a major operational bottleneck in oncology. Most high-cost oncology drugs (targeted therapies, immunotherapy, biosimilars) require authorization before administration, and treatment delays caused by auth failures are a patient care crisis as well as a revenue issue.

Oncology PA Best Practices

• Submit PA before first dose: Even for urgent cases, initiate authorization at the time of treatment planning, average PA turnaround for oncology drugs is 3–7 business days for standard review, 24–72 hours for expedited
• Include biomarker data: Most immunotherapy PAs require PD-L1 expression, TMB, MSI status, or EGFR/ALK mutation documentation. Missing biomarker data is the #1 reason for oncology PA initial denial
• Line of therapy documentation: Payers require documentation of prior treatment lines. If pembrolizumab is being used as first-line, document that clearly, if second-line, document what first-line therapy failed and when
• NCCN guideline citation: Reference the specific NCCN category (1, 2A, 2B) for the requested regimen. Category 1 recommendations have the highest approval rates; Category 2B requires additional medical necessity justification
• Peer-to-peer appeals: Oncology PA denials have the highest overturn rate through peer-to-peer review (62–78% overturn), always pursue P2P before sending written appeals

6. Radiation Oncology Billing Overview

Medical oncology and radiation oncology billing are managed separately. Radiation oncology practices bill under a distinct code set involving treatment planning, simulation, and delivery codes. Key codes for context:

• 77261–77263: Radiation treatment planning, simple, intermediate, complex. Documentation must describe fields, beam configuration, and plan complexity
• 77300: Basic dosimetry calculation, billed per treatment plan modification
• 77385–77386: Intensity modulated radiation therapy (IMRT) delivery, simple vs. complex. IMRT requires prior auth from most payers and documentation of why 3D conformal radiation is insufficient
• 77427: Radiation treatment management, weekly physician treatment management, per 5 fractions. Bill once per 5 fractions completed
• G6001–G6017: IMRT planning and delivery HCPCS codes, used by some payers in place of CPT codes for radiation services

Oncology billing demands coding expertise that most generalist billing companies can't provide. RCMAXIS fields dedicated oncology revenue cycle specialists who understand infusion hierarchy, drug J-code precision, and the PA workflow for high-cost biologics. Start with a free revenue assessment to identify where your oncology practice is losing revenue.

Oncology Audit Exposure: Drug Units, Wastage, and Administration Sequence

Oncology claims carry the highest dollar value per line, so they get the most detailed review. Drug lines are checked for units that match the J-code descriptor and the dose in the record, for the correct National Drug Code, and for the discarded-drug modifiers. Administration lines are checked for the infusion hierarchy, the route, and the documented times. A mismatch between what was ordered, what was mixed, and what was billed is the usual finding.

Because buy-and-bill practices are paid on the drug itself, a units error is a payment error, and it repeats on every patient on the same regimen. Contractors can look back three years, and biologics are expensive enough that a small per-claim difference becomes a large repayment. Reconcile drug purchases, administration records, and billed units each month, and keep the reconciliation on file.

What Infusion Coding Errors Cost an Oncology Practice

Infusion codes are where small errors turn into real money. At 2026 non-facility rates, the first hour of a chemotherapy infusion under 96413 pays $133.27, while a non-chemotherapy initial infusion under 96365 pays $67.14. Code a chemo drug infusion as 96365 and you give up $66.13 each time.

A practice that gives 200 infusions a month with 8% coded to the wrong family loses $1,058.08 a month, or $12,697 a year, before counting concurrent and hydration add-ons such as 96368 ($20.71) and 96360 ($33.40). Drug payments, billed separately, are far larger, so a unit error there costs more still.

Frequently Asked Questions About Oncology

What are the chemotherapy infusion CPT codes?

Chemotherapy infusion CPT codes start with 96413 for the first hour, 96415 for each additional hour, and 96417 for each additional sequential drug. 96409 and 96411 cover IV push, 96416 starts infusions over 8 hours using a pump, and 96401 covers subcutaneous or intramuscular injections.

What CPT codes are used to bill FOLFOX?

FOLFOX is commonly reported with 96413 and 96415 for oxaliplatin, 96368 once for concurrent leucovorin, 96411 for the 5-FU push, and 96416 to start the 5-FU pump. Drug lines use J9263, J0640 and J9190. Confirm pump disconnect rules with each payer.

Is immunotherapy billed with chemotherapy codes?

Often yes. Medicare's manual extends the chemotherapy administration codes to monoclonal antibodies and other biologic response modifiers, which covers most checkpoint inhibitors. Since 2025 CMS also looks at the intensity of the service, not the drug name alone, so check your MAC's billing article.

How are chemotherapy administration codes different from standard infusion codes?

The article says chemo administration codes carry higher reimbursement and depend on the route (IV push or infusion), the duration, and whether the service is the primary one. They're separate from the therapeutic infusion codes 96365 to 96368.

Which codes are used for antiemetics and growth factors given during an oncology visit?

Non-chemotherapy infusions such as antiemetics, growth factors, and supportive care drugs use the therapeutic infusion codes (96365 to 96368), not the chemotherapy codes, according to the article.

What is buy-and-bill?

The practice buys drugs wholesale and bills payers at the allowed amount. The article calls it a significant part of oncology revenue, which is why drug billing accuracy matters so much.